Pluvicto Approved Earlier in Metastatic Prostate Cancer M. Alexander Otto, PA, MMSc August 03, 2026

https://www.medscape.com/viewarticle/pluvicto-approved-earlier-metastatic-prostate-cancer-2026a1000qcj?src= The FDA has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive or -sensitive prostate cancer (formerly known as metastatic hormone-sensitive prostate cancer).